Edwards Lifesciences Corp (EW)vsIradimed Co (IRMD)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
IRMD
Iradimed Co
$101.78
+0.80%
HEALTHCARE · Cap: $1.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 7139% more annual revenue ($6.07B vs $83.81M). IRMD leads profitability with a 26.8% profit margin vs 17.7%. EW appears more attractively valued with a PEG of 2.14. IRMD earns a higher WallStSmart Score of 60/100 (C).
EW
Buy55
out of 100
Grade: C
IRMD
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Margin of Safety
-26.7%
Fair Value
$81.34
Current Price
$101.78
$20.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Strong operational efficiency at 31.3%
Every $100 of equity generates 25 in profit
Keeps 27 of every $100 in revenue as profit
17.0% revenue growth
Earnings expanding 24.8% YoY
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Trading at 13.8x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Return on Equity, Profit Margin. Profitability is solid with margins at 26.8% and operating margin at 31.3%. Revenue growth of 17.0% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, PEG Ratio. A P/E of 56.9x leaves little room for execution misses.
Key Dynamics to Monitor
EW profiles as a mature stock while IRMD is a growth play — different risk/reward profiles.
IRMD carries more volatility with a beta of 1.10 — expect wider price swings.
IRMD is growing revenue faster at 17.0% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
IRMD scores higher overall (60/100 vs 55/100), backed by strong 26.8% margins and 17.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?